Clinical Trials

Find a Trial

Trial Results

16 protocol(s) meet the specified criteria
ADVL1514OPEN TO ACCRUAL
A PHASE 1 STUDY OF ABI-009 (NAB-RAPAMYCIN) IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN
APX-CLN-0011OPEN TO ACCRUAL
A Phase 1 Dose-escalation Study of APX3330 in Patients with Advanced Solid Tumors and a Dose-expansion Cohort of Patients with Advanced Ductal Adenocarcinoma of the Pancreas
CC9078OPEN TO ACCRUAL
Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW2992)in Combination with Capecitabine for Advanced Solid Tumors and Pancretico- Biliary Cancers
I9L-MC-JZCAOPEN TO ACCRUAL
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination with Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
INCB62079-101OPEN TO ACCRUAL
A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
MS100015-0019OPEN TO ACCRUAL
An Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors
MS200770-0001OPEN TO ACCRUAL
A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination with Palliative Radiotherapy in Subjects with Solid Tumors
PHO-ASTELLAS-9766-CL-0046OPEN TO ACCRUAL
A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients.
PHO-COG-CROOP-ADVL1212OPEN TO ACCRUAL
ADVL1212, A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
PHO-COG-CROOP-ADVL1414OPEN TO ACCRUAL
A Phase 1 Study of Selinexor (KPT-330, IND# 125052), A Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors
PHO-CROOP-COG-ADVL1515OPEN TO ACCRUAL
ADVL1515, A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
PHO-CROOP-COG-ADVL1615OPEN TO ACCRUAL
A PHASE 1 STUDY OF PEVONEDISTAT (MLN4924, IND# 136078), A NEDD8 ACTIVATING ENZYME (NAE) INHIBITOR, IN COMBINATION WITH TEMOZOLOMIDE AND IRINOTECAN IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
PHO-LILLY-CROOP-ADVL1416OPEN TO ACCRUAL
A PHASE 1 STUDY OF RAMUCIRUMAB, A HUMAN MONOCLONAL ANTIBODY AGAINST THE VASCULAR ENDOTHELIAL GROWTH FACTOR-2 (VEGFR-2) RECEPTOR IN CHILDREN WITH REFRACTORY SOLID TUMORS, INCLUDING CNS TUMORS
PHO-LILLY-PRADHAN-JGDNOPEN TO ACCRUAL
I5B-MC-JGDN(a) A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors
PHO-MILL-DELG-1209009655OPEN TO ACCRUAL
A phase I study evaluating the addition of bortezomib to an established acute graft versus host disease (aGVHD) prophylaxis regimen in pediatric allogeneic hematopoietic stem cell transplant (alloHSCT) patients
SURG-NHLBI-FINET-SENECAOPEN TO ACCRUAL
A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo- Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy